Chronic kidney disease after liver, cardiac, lung, heart–lung, and hematopoietic stem cell transplant

Patient survival after cardiac, liver, and hematopoietic stem cell transplant (HSCT) is improving; however, this survival is limited by substantial pretransplant and treatment-related toxicities. A major cause of morbidity and mortality after transplant is chronic kidney disease (CKD). Although the majority of CKD after transplant is attributed to the use of calcineurin inhibitors, various other conditions such as thrombotic microangiopathy, nephrotic syndrome, and focal segmental glomerulosclerosis have been described. Though the immunosuppression used for each of the transplant types, cardiac, liver and HSCT is similar, the risk factors for developing CKD and the CKD severity described in patients after transplant vary. As the indications for transplant and the long-term survival improves for these children, so will the burden of CKD. Nephrologists should be involved early in the pretransplant workup of these patients. Transplant physicians and nephrologists will need to work together to identify those patients at risk of developing CKD early to prevent its development and progression to end-stage renal disease

Evolution of Complications and Mortality of Living Liver Donation in Europe

16th Annual Congress of the International-Liver-Transplantation-Society -- JUN 16-19, 2010 -- Hong Kong, PEOPLES R CHINAWOS: 000278428000160Int Liver Transplantat So

LIVING DONOR LIVER TRANSPLANTATION: A EUROPEAN LIVER TRANSPLANT REGISTRY (ELTR) REPORT ON 2634 CASES

15th Annual Congress of the International-Liver-Transplantation-Society -- JUL 08-11, 2009 -- New York, NYWOS: 000267792300067Int Liver Transplantat So